BioSpace News Archive

KA Imaging’s portable dual-energy X-ray detector has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Reveal™ enables bone and soft-tissue differentiation without motion artifacts in a single X-ray exposure.

Diversity of Experience Brings New Insight and Proven Leadership to Support Advanced Commercial Structure While Balancing Continuity in Key Positions Molly Henderson Named Chief Financial Officer Jason Smith Named General Counsel and Chief Compliance Officer Polly A. Murphy, DVM, Ph.D., Named Chief Business Officer PRINCETON, N.J.--( BUSINESS WIRE )-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedica

AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a company focused on developing and commercializing innovative therapeutics for human aging, and Lineage Cell Th

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, today announced the appointment of Dean J. Mitchell as board Chairman. Mr. Mitchell is an accomplished executive who brings more than three decades of experience in the biophar

Yulong Eco-Materials Limited (OTC PINK:YECO ) today announced that it intends to build an incubator laboratory for development of cell and extracellular vesicle (EV) based therapeutics.

TScan Therapeutics, a biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies in oncology, announced plans to file two Investigational New Drug applications in their liquid tumor program in 2021.

Adagio Therapeutics, Inc., a company focused on the development of best-in-class antibodies to provide broad protection against SARS-CoV-2, SARS-CoV-1 and additional circulating bat coronaviruses, announced it has strengthened its management team with the addition of Eric Kimble as Chief Commercial Officer and Ed Campanaro as Senior Vice President of Clinical Operations.

Orthofix Medical Inc. announced support for the U.S. Food and Drug Administration Medical Devices Advisory Committee, Orthopaedic and Rehabilitative Devices Panel recommendation to require robust and complete clinical data for the proposed reclassification of bone growth stimulators from Class III to Class II with “special controls” to ensure patient safety and therapy efficacy.

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will participate at the upcoming conferences in September 2020: H. C. Wainwright 22nd Annual Global Investment Conference Date: Monday,

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses